Hinge Health, Inc. SEC Filings

Hinge Health, Inc. Chief Financial Officer James Budge reported selling 10,491 shares of Class A common stock on 12/22/2025 in an open-market transaction. The shares were sold at a weighted average price of $48.4069 per share, with individual sale prices ranging from $47.81 to $48.74. The transaction was executed under a Rule 10b5-1 trading plan that he adopted on June 12, 2025. Following this sale, Budge beneficially owns 441,174 shares of Hinge Health Class A common stock, held directly.

HNGE has a shareholder filing a notice of proposed sale under Rule 144 for up to 15,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC with an aggregate market value of $708,750.00, based on the information provided. The filing notes that 37,919,155 shares of this class were outstanding, and the approximate sale date listed is 12/22/2025 on the NYSE.

The 15,000 shares to be sold were acquired on 04/01/2023 as performance stock units from the issuer. Over the prior three months, the same account completed a Rule 10b5-1 sale of 15,000 common shares on 11/21/2025 for gross proceeds of $683,487.00. By signing the notice, the seller represents that they do not know of undisclosed material adverse information about the issuer’s operations.

James Budge filed a notice under Rule 144 to sell 10,491 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of 495,699.75. The shares relate to restricted stock units acquired from the issuer on 12/01/2025, when 37,919,155 shares of common stock were outstanding. In the past three months, 10b5-1 sales for James Budge already disposed of 44,589 and 781 shares of common stock for gross proceeds of 2,116,778.06 and 34,973.18, respectively. By signing, the seller represents that he is not aware of undisclosed material adverse information about the issuer’s operations.

Hinge Health, Inc. CEO, Co‑Founder, director and 10% owner reported insider transactions dated December 15, 2025. On that date, he converted 166,670 shares of Class B common stock into Class A common stock at an exercise price of $0, then disposed of the same 166,670 Class A shares in open‑market sales.

The first sale covered 161,250 Class A shares at a weighted average price of $48.5031, within a range of $47.98 to $48.96. The second sale covered 5,420 shares at a weighted average price of $49.2962, within a range of $49.00 to $49.58. All sales were made under a Rule 10b5‑1 trading plan adopted on September 11, 2025.

After these transactions, he beneficially owned 14,543,427 shares of Class B common stock directly, plus 515,705 Class B shares and 35,470 Class A shares indirectly through his spouse.

A shareholder of the issuer filed a notice to sell 166,670 shares of common stock. The shares are planned to be sold through Morgan Stanley Smith Barney LLC on or about 12/15/2025 on the NYSE, with an aggregate market value listed as 8,283,499.00.

The securities were acquired on 03/22/2023 as restricted stock awards directly from the issuer, and the filing notes that 37,919,155 common shares were outstanding. By signing the notice, the seller represents that they are not aware of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.

Hinge Health, Inc. has an ownership report showing that Jane Street Group, LLC and related entities report beneficial ownership of 2,130,181 Class A common shares, representing 5.6% of the outstanding class as of 12/08/2025.

The shares are reported with no sole voting or dispositive power and shared voting and dispositive power over 2,130,181 shares. The report covers Jane Street Group, LLC together with Jane Street Capital, LLC, Jane Street Options, LLC, and Jane Street Global Trading, LLC. The certification states that the securities were not acquired and are not held for the purpose of changing or influencing the control of Hinge Health.

Hinge Health, Inc. Chief Financial Officer James Budge reported a change in his holdings of the company’s Class A common stock. On 12/11/2025, he disposed of 20,000 shares at a reported price of $0 under transaction code G, leaving him with 451,665 shares of Class A common stock held directly after the transaction. This filing was made as a Form 4 by a single reporting person.

Hinge Health, Inc. reported an insider transaction by a person who is a director, CEO, co‑founder and 10% owner. On 12/10/2025, the insider converted 11,680 shares of Class B Common Stock into 11,680 shares of Class A Common Stock at a stated price of $0 per share. On 12/12/2025, those 11,680 Class A shares were transferred as a gift, leaving the insider with 0 directly held Class A shares.

Following these transactions, the insider reported 14,710,097 derivative securities related to Class B Common Stock held directly, and an additional 515,705 derivative securities and 35,470 Class A shares held indirectly through a spouse. Each share of Class B Common Stock is convertible into one share of Class A Common Stock under conditions described in the company’s charter.

Hinge Health, Inc. reported an insider-related share sale involving a major shareholder. A director and 10% owner filed to report sales made by affiliated Bessemer venture funds on December 5, 2025. Bessemer Venture Partners X L.P. sold 2,614 shares of Class A common stock and Bessemer Venture Partners X Institutional L.P. sold 2,453 shares at a weighted average price of $50.0166, in multiple trades between $50.00 and $50.12. The reporting person is a partner at Bessemer Venture Partners and describes only an indirect, passive economic interest in these fund-held shares, formally disclaiming beneficial ownership beyond any pecuniary interest.